Buy Or Sell Opportunity • Jun 08
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 26% to ₩11,380. The fair value is estimated to be ₩14,908, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 49%. Revenue is forecast to grow by 9.4% in a year. Earnings are forecast to decline by 5.7% in the next year. Buy Or Sell Opportunity • Apr 24
Now 23% overvalued Over the last 90 days, the stock has fallen 3.4% to ₩16,950. The fair value is estimated to be ₩13,809, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 63%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 3.4% in the next 2 years. New Risk • Apr 01
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 23% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Anuncio • Mar 14
VT Co., Ltd., Annual General Meeting, Mar 27, 2026 VT Co., Ltd., Annual General Meeting, Mar 27, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 139, saneopdanji-gil, gyeonggi-do, paju South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₩14,310, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 157% over the past three years. Buy Or Sell Opportunity • Feb 02
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to ₩19,820. The fair value is estimated to be ₩25,176, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 78%. Revenue is forecast to grow by 9.4% in a year. Earnings are forecast to decline by 31% in the next year. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩18,880, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Personal Products industry in South Korea. Total returns to shareholders of 232% over the past three years. Buy Or Sell Opportunity • Dec 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 39% to ₩19,040. The fair value is estimated to be ₩24,137, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 78%. Revenue is forecast to grow by 9.4% in a year. Earnings are forecast to decline by 31% in the next year. New Risk • Nov 19
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 37% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 37% per year for the foreseeable future. High level of non-cash earnings (27% accrual ratio). Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: ₩577 (vs ₩481 in 2Q 2024) Second quarter 2025 results: EPS: ₩577 (up from ₩481 in 2Q 2024). Revenue: ₩111.5b (down 1.6% from 2Q 2024). Net income: ₩20.5b (up 33% from 2Q 2024). Profit margin: 18% (up from 14% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Jun 09
Now 20% undervalued Over the last 90 days, the stock has risen 28% to ₩42,900. The fair value is estimated to be ₩53,861, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 88%. New Risk • May 20
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Apr 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩37,800, the stock trades at a trailing P/E ratio of 13.7x. Average forward P/E is 10x in the Personal Products industry in South Korea. Total returns to shareholders of 436% over the past three years. Anuncio • Mar 13
VT Co., Ltd., Annual General Meeting, Mar 27, 2025 VT Co., Ltd., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 139, saneopdanji-gil, gyeonggi-do, paju South Korea New Risk • Dec 09
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Anuncio • Dec 04
VT Co., Ltd. (KOSDAQ:A018290) agreed to acquire ENC Co., Ltd for KRW 6.48 billion. VT Co., Ltd. (KOSDAQ:A018290) agreed to acquire ENC Co., Ltd for KRW 6.48 billion on December 2, 2024. New Risk • Dec 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩35,700, the stock trades at a trailing P/E ratio of 16.7x. Average forward P/E is 9x in the Personal Products industry in South Korea. Total returns to shareholders of 372% over the past three years. Buy Or Sell Opportunity • Nov 13
Now 22% undervalued Over the last 90 days, the stock has risen 1.3% to ₩30,700. The fair value is estimated to be ₩39,353, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 47%. Buy Or Sell Opportunity • Oct 16
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.8% to ₩31,850. The fair value is estimated to be ₩39,855, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 47%. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩35,200, the stock trades at a trailing P/E ratio of 23.7x. Average forward P/E is 13x in the Personal Products industry in South Korea. Total returns to shareholders of 325% over the past three years. Buy Or Sell Opportunity • Aug 21
Now 21% undervalued Over the last 90 days, the stock has risen 12% to ₩30,650. The fair value is estimated to be ₩38,746, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 47%. Reported Earnings • Aug 15
Second quarter 2024 earnings released: EPS: ₩481 (vs ₩154 in 2Q 2023) Second quarter 2024 results: EPS: ₩481 (up from ₩154 in 2Q 2023). Revenue: ₩113.4b (up 52% from 2Q 2023). Net income: ₩15.4b (up 203% from 2Q 2023). Profit margin: 14% (up from 6.8% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to ₩28,900, the stock trades at a trailing P/E ratio of 24.2x. Average forward P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 226% over the past three years. New Risk • Aug 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩37,850, the stock trades at a trailing P/E ratio of 31.7x. Average forward P/E is 15x in the Personal Products industry in South Korea. Total returns to shareholders of 325% over the past three years. Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩32,300, the stock trades at a trailing P/E ratio of 27.1x. Average forward P/E is 16x in the Personal Products industry in South Korea. Total returns to shareholders of 242% over the past three years. Valuation Update With 7 Day Price Move • May 29
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩31,000, the stock trades at a trailing P/E ratio of 26.2x. Average forward P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 228% over the past three years. Reported Earnings • May 18
First quarter 2024 earnings released: EPS: ₩451 (vs ₩30.00 in 1Q 2023) First quarter 2024 results: EPS: ₩451 (up from ₩30.00 in 1Q 2023). Revenue: ₩101.8b (up 113% from 1Q 2023). Net income: ₩16.0b (up ₩15.1b from 1Q 2023). Profit margin: 16% (up from 2.0% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩25,400, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 179% over the past three years. Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩22,250, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 13x in the Personal Products industry in South Korea. Total returns to shareholders of 164% over the past three years. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩19,390, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Personal Products industry in South Korea. Total returns to shareholders of 137% over the past three years. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩18,940, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 12x in the Personal Products industry in South Korea. Total returns to shareholders of 125% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩26,826 per share. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩17,730, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 15x in the Personal Products industry in South Korea. Total returns to shareholders of 105% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩24,953 per share. Valuation Update With 7 Day Price Move • Nov 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩17,650, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 98% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩28,713 per share. Reported Earnings • Nov 13
Third quarter 2023 earnings released: EPS: ₩233 (vs ₩68.00 in 3Q 2022) Third quarter 2023 results: EPS: ₩233 (up from ₩68.00 in 3Q 2022). Revenue: ₩84.1b (up 57% from 3Q 2022). Net income: ₩7.93b (up 264% from 3Q 2022). Profit margin: 9.4% (up from 4.1% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩16,500, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 87% over the past three years. Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩16,400, the stock trades at a trailing P/E ratio of 70.7x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 79% over the past three years. Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩9,920, the stock trades at a trailing P/E ratio of 65.8x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 10.0% over the past three years. New Risk • Jul 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.2% net profit margin). Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩9,190, the stock trades at a trailing P/E ratio of 59.1x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 8.6% over the past three years. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩7,260, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total loss to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩6,290, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 33% over the past three years. Reported Earnings • May 18
First quarter 2022 earnings released: EPS: ₩213 (vs ₩261 in 1Q 2021) First quarter 2022 results: EPS: ₩213 (down from ₩261 in 1Q 2021). Revenue: ₩57.3b (up 29% from 1Q 2021). Net income: ₩7.01b (down 17% from 1Q 2021). Profit margin: 12% (down from 19% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 18
Third quarter 2021 earnings released: EPS ₩164 (vs ₩27.00 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩47.5b (up 117% from 3Q 2020). Net income: ₩5.39b (up ₩4.51b from 3Q 2020). Profit margin: 11% (up from 4.0% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • May 12
First quarter 2021 earnings released: EPS ₩261 (vs ₩113 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩44.4b (up 29% from 1Q 2020). Net income: ₩8.46b (up 146% from 1Q 2020). Profit margin: 19% (up from 10.0% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Anuncio • Feb 08
VT GMP Co.,Ltd announced that it has received KRW 10.5 billion in funding On February 8, 2021, VT GMP Co.,Ltd (KOSDAQ:A018290) closed the transaction. Price Target Changed • Jan 07
Price target raised to ₩16,500 Up from ₩14,500, the current price target is provided by 1 analyst. The new target price is 88% above the current share price of ₩8,760. As of last close, the stock is down 2.2% over the past year. Is New 90 Day High Low • Oct 26
New 90-day low: ₩8,060 The company is down 8.0% from its price of ₩8,760 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩14,994 per share. Anuncio • Sep 22
Changyoung Kang, Hana Cho, Dongyoon Kang, Jeong-Hee Song, Park Jong Gap, Jieun Jang and others acquired an unknown stake in GMP Co., Ltd. (KOSDAQ:A018290) from KDB Private Equity and Korea Trade Insurance Corporation. Changyoung Kang, Hana Cho, Dongyoon Kang, Jeong-Hee Song, Park Jong Gap, Jieun Jang and others acquired an unknown stake in GMP Co., Ltd. (KOSDAQ:A018290) from KDB Private Equity and Korea Trade Insurance Corporation on October 31, 2016. Park Jong Gap acquired 2.3 million shares. Korea Development Bank sold 1.6 million shares and Korea Trade Insurance Corporation sold 0.6 million shares to a few buyers. Changyoung Kang, Hana Cho, Dongyoon Kang and Jeong-Hee Song acquired 0.2 million shares, 0.5 million shares, 0.16 million shares, 0.12 million shares respectively.
Changyoung Kang, Hana Cho, Dongyoon Kang, Jeong-Hee Song, Park Jong Gap, Jieun Jang and others completed the acquisition of an unknown stake in GMP Co., Ltd. (KOSDAQ:A018290) from KDB Private Equity and Korea Trade Insurance Corporation on October 31, 2016.